Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.77 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.77 |
| ▸ | TTR | P02766 | 3/20 | 0.77 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.77 |
| ▸ | ABL1 | P00519 | 4/20 | 0.69 |
| ▸ | BCR | P11274 | 4/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pinosylvin Methyl Ether SCHEMBL9419826 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPTKMT2AUSP2 | |
| Pinosylvin Methyl Ether SCHEMBL29928865 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPTKMT2AUSP2 | |
| Pinosylvin Methyl Ether SCHEMBL1650248 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPTKMT2AUSP2 | |
| Pinosylvin Methyl Ether SCHEMBL30334927 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPTKMT2AUSP2 | |
| Pterostilbene SCHEMBL3476943 | 0.89 | NQO2 (0.86) | KDM4EMEN1MAPTKMT2AUSP2 | |
| Pterostilbene SCHEMBL3476941 | 0.89 | NQO2 (0.86) | KDM4EMEN1MAPTKMT2AUSP2 | |
| 3,5-O-Dimethylpinosylvin SCHEMBL918726 | 0.88 | KDM4E (0.79) | KDM4EMEN1MAPTKMT2AUSP2 | |
| 3,5-O-Dimethylpinosylvin SCHEMBL9419809 | 0.88 | KDM4E (0.79) | KDM4EMEN1MAPTKMT2AUSP2 | |
| 3,5-O-Dimethylpinosylvin SCHEMBL918727 | 0.88 | KDM4E (0.79) | KDM4EMEN1MAPTKMT2AUSP2 | |
| SCHEMBL23410069 | 0.87 | ABL1 (0.90) | KDM4EMEN1MAPTKMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115541792-B | Quality control method and application of Chinese pine knot formula particles | 北京康仁堂药业有限公司 | 2024-12-20 | — | — | CN | claimed |
| EP-4436538-A1 | COSMETIC OR PHARMACEUTICAL PREPARATION FOR SKIN CARE AND IMPROVING SKIN CONDITION | Merryvital AG (CH) | 2024-10-02 | — | — | EP | claimed |
| CN-118401224-A | Cosmetic or cosmeceutical product for skin care and improving skin condition | 迈瑞维拓股份公司 | 2024-07-26 | — | — | CN | claimed |
| CN-113842390-B | Lindera fruticosa active ingredient composition with gastric ulcer prevention and treatment effect, and preparation method and application thereof | 河南中医药大学 | 2024-03-12 | — | — | CN | claimed |
| WO-2023094852-A1 | COSMETIC OR PHARMACEUTICAL PREPARATION FOR SKIN CARE AND IMPROVING SKIN CONDITION | MERRYVITAL AG (CH) | 2023-06-01 | — | — | WO | claimed |
| US-20230012268-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) | 2023-01-12 | — | — | US | claimed |
| CN-115541792-A | Quality control method of Chinese pine knot formula granules and application thereof | 北京康仁堂药业有限公司 | 2022-12-30 | — | — | CN | claimed |
| EP-4072558-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR | Buzzelet Development And Technologies Ltd (IL) | 2022-10-19 | — | — | EP | claimed |
| US-20220233463-A1 | LOCAL ANESTHETIC COMPRISING A TRP CHANNEL MODULATOR | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) | 2022-07-28 | — | — | US | claimed |
| EP-4017486-A1 | COMPOSITONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND USES THEREOF | Buzzelet Development And Technologies Ltd (IL) | 2022-06-29 | — | — | EP | claimed |
| WO-2021033149-A1 | COMPOSITONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND USES THEREOF | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD. (IL) | 2021-02-25 | — | — | WO | claimed |
| WO-2020230071-A1 | LOCAL ANESTHETIC COMPRISING A TRP CHANNEL MODULATOR | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD. (IL) | 2020-11-19 | — | — | WO | claimed |
| US-20130245070-A1 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-09-19 | — | — | US | claimed |
| US-20090253782-A1 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof | CORNELL RESEARCH FOUNDATION, INC. | 2009-10-08 | — | — | US | claimed |
| WO-2009118338-A2 | USE OF A POLYPHENOLIC TYPE COMPOUND FOR PREVENTING OR TREATING A POLYGLUTAMINE EXPANSION NEURODEGENERATIVE DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-10-01 | — | — | WO | claimed |
| EP-2005941-A2 | Cellular rejuvenation compounds | Henkel AG & Co. KGaA (DE) | 2008-12-24 | — | — | EP | claimed |
| US-20080139650-A1 | Fungicidally Active Polymer Dispersions And Use Thereof | CELANESE EMULSIONS GMBH (DE) | 2008-06-12 | — | — | US | claimed |
| WO-2008011083-A2 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USE THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-20070292545-A1 | ANTI-INFECTIVE AGENTS AND METHODS OF USE | WISYS TECHNOLOGY FOUNDATION | 2007-12-20 | — | — | US | claimed |
| CN-1553887-A | Method for separating phenolic substances or juvabiones from wood containing nodular wood | �����ᡤ����ķ��ķ | 2004-12-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139650-A1 | Fungicidally Active Polymer Dispersions And Use Thereof | CBR3, CBR1, CYP3A4 | KDM4E 1199/4885MEN1 2062/4885MAPT 3690/4885 |
| US-20130245070-A1 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME | ARG2, ARG1, OTC | KDM4E 1426/4885MEN1 3845/4885MAPT 3632/4885 |
| US-20070292545-A1 | ANTI-INFECTIVE AGENTS AND METHODS OF USE | H1-3, H1-0, H1-2 | KDM4E 1612/4885MEN1 2664/4885MAPT 4879/4885 |
| US-20090253782-A1 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof | ARG2, ARG1, OTC | KDM4E 1521/4885MEN1 3962/4885MAPT 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.